Ginkgo bioworks and xwell implement expanded cdc traveler-based genomic surveillance program to test for more than 30 known pathogens

The program can be an effective early warning system for public health and national security officials, leveraging voluntary nasal and wastewater sampling from international travelers at major u.s. airports boston , nov. 6, 2023 /prnewswire/ -- ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, and xwell, inc. (nasdaq: xwel) today announced they are expanding their work with the u.s. centers for disease control and prevention's (cdc's) traveler-based genomic surveillance program (tgs) to test for more than 30 additional priority pathogens, in addition to sars-cov-2. tgs is a flexible, multimodal platform that consists of three complementary approaches of sample collection from arriving international travelers at u.s. airports, including voluntary nasal swabbing, aircraft wastewater, and airport wastewater sampling to enhance early detection of new sars-cov-2 variants and other pathogens, and fills gaps in global surveillance.
DNA Ratings Summary
DNA Quant Ranking